We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis

Doshi BS, Witmer CM. Haemophilia. 2021 Jul;27(4):e551-e553

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers

Kotani N, Yoneyama K, Kawakami N, et al. Clin Pharmacol Drug Dev 2019;8:702–712.

Emicizumab for hemophilia A without inhibitors

Cafuir L, Kruse-Jarres R, Mancuso ME, Kempton CL. Expert Rev Hematol. 2019;12(7):515-524.

Emicizumab and thrombosis: The story so far.

Makris M, Iorio A, Lenting PJ. J Thromb Haemost 2019;17:1269–1272.    

Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis‐treated haemophilia A patients with inhibitors

Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Br J Haematol. 2020 Sep;190(5):727-735

Surgery with emicizumab prophylaxis for two paediatric patients with severe haemophilia A with inhibitors

Lockhart M, Tardy-Poncet B, Montmartin A, et al. Pediatr Blood Cancer. 2021 Jul;68(7):e29041

Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity

Sampei Z, Igawa T, Soeda T, et al. MAbs. 2015;7(1):120-128.

Benefits of prophylactic emicizumab in enhancing immune tolerance induction in a boy with hemophilia A and very high inhibitor titer

Sirachainan N, Chuansumrit A, Parapakpenjune S, et al. Pediatr Blood Cancer. 2021 Sep;68(9):e29111

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery

Jiménez-Yuste V, Rodríguez-Merchán EC, Matsushita T, Holme PA. Haemophilia. 2021 Jul;27(4):519-530